{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:19:14Z","timestamp":1788689954134,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"UpToDate"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.mcna.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T19:40:56Z","timestamp":1540323656000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Proton Pump Inhibitors"],"prefix":"10.1016","volume":"103","author":[{"given":"Stuart Jon","family":"Spechler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2018.08.001_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.12613","article-title":"We have had a gutful: the need for deprescribing proton pump inhibitors","volume":"43","author":"Naunton","year":"2018","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2018.08.001_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1152\/physrev.1995.75.1.155","article-title":"Gastric acid secretion","volume":"75","author":"Hersey","year":"1995","journal-title":"Physiol Rev"},{"key":"10.1016\/j.mcna.2018.08.001_bib4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.mcna.2018.08.001_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0016-5085(98)70010-1","article-title":"Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects","volume":"115","author":"Peghini","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2018.08.001_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1572-0241.2003.07304.x","article-title":"Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure","volume":"98","author":"Ours","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mcna.2018.08.001_bib7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/07853890.2011.554429","article-title":"Dexlansoprazole MR: a review","volume":"43","author":"Hershcovici","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.mcna.2018.08.001_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2036.2006.03191.x","article-title":"Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms","volume":"25","author":"Katz","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.mcna.2018.08.001_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2005.02712.x","article-title":"Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure","volume":"22","author":"Katz","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib10","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1007\/s10620-009-0951-9","article-title":"Potential anti-inflammatory effects of the proton pump inhibitors: a review and discussion of the clinical implications","volume":"54","author":"Kedika","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.mcna.2018.08.001_bib11","doi-asserted-by":"crossref","first-page":"10993","DOI":"10.1074\/jbc.M210328200","article-title":"A\u00a0novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical","volume":"278","author":"Biswas","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.mcna.2018.08.001_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00210-008-0314-7","article-title":"Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin","volume":"378","author":"Pastoris","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.mcna.2018.08.001_bib13","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbrc.2006.04.170","article-title":"Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells","volume":"345","author":"Becker","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.mcna.2018.08.001_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0891-5849(96)00180-3","article-title":"Omeprazole attenuates oxygen-derived free radical production from human neutrophils","volume":"21","author":"Suzuki","year":"1996","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.mcna.2018.08.001_bib15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/00003246-200205000-00026","article-title":"Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity","volume":"30","author":"Zedtwitz-Liebenstein","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.mcna.2018.08.001_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.33.5.617","article-title":"Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245","volume":"33","author":"Wandall","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.mcna.2018.08.001_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00011-006-6056-4","article-title":"Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors","volume":"55","author":"Handa","year":"2006","journal-title":"Inflamm Res"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2018.08.001_bib18","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/00004836-199506002-00025","article-title":"Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori","volume":"20","author":"Suzuki","year":"1995","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.mcna.2018.08.001_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00011-006-6127-6","article-title":"The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in\u00a0vitro: restoration by a K+ ionophore","volume":"56","author":"Martins de Oliveira","year":"2007","journal-title":"Inflamm Res"},{"key":"10.1016\/j.mcna.2018.08.001_bib20","doi-asserted-by":"crossref","first-page":"32175","DOI":"10.1074\/jbc.M600943200","article-title":"Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d\/29) and alphaMbeta2 (CD11b\/18) of eosinophils","volume":"281","author":"Barthel","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"2\u20133","key":"10.1016\/j.mcna.2018.08.001_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejphar.2004.12.042","article-title":"The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells","volume":"509","author":"Sasaki","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mcna.2018.08.001_bib22","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1053\/j.gastro.2007.08.017","article-title":"Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment","volume":"133","author":"Furuta","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2018.08.001_bib23","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/gutjnl-2012-302250","article-title":"Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD","volume":"62","author":"Cheng","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.mcna.2018.08.001_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases \u2013 a position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.mcna.2018.08.001_bib25","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2016.5657","article-title":"Association of acute gastroesophageal reflux disease with esophageal histologic changes","volume":"315","author":"Dunbar","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mcna.2018.08.001_bib26","first-page":"728","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mcna.2018.08.001_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.11622\/smedj.2014087","article-title":"Inappropriate use of proton pump inhibitors in a local setting","volume":"55","author":"Chia","year":"2014","journal-title":"Singapore Med J"},{"key":"10.1016\/j.mcna.2018.08.001_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11845-009-0426-1","article-title":"Inappropriate use of proton pump inhibitors","volume":"179","author":"Molloy","year":"2010","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.mcna.2018.08.001_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000481813","article-title":"Intestinal dysbiosis secondary to proton-pump inhibitor use","volume":"97","author":"Naito","year":"2018","journal-title":"Digestion"},{"key":"10.1016\/j.mcna.2018.08.001_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology","volume":"42","author":"Lundell","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.physiol.63.1.119","article-title":"The gastrins: their production and biological activities","volume":"63","author":"Dockray","year":"2001","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.mcna.2018.08.001_bib32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/gast.2003.50091","article-title":"Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor","volume":"124","author":"Haigh","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2018.08.001_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.39.5.649","article-title":"Marked increase in gastric acid secretory capacity after omeprazole treatment","volume":"39","author":"Waldum","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.mcna.2018.08.001_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2036.2004.02271.x","article-title":"Rebound acid hypersecretion after long-term inhibition of gastric acid secretion","volume":"21","author":"Fossmark","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.08.001_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000199381","article-title":"Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion","volume":"35","author":"Havu","year":"1986","journal-title":"Digestion"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.08.001_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000200923","article-title":"Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy","volume":"51","author":"Freston","year":"1992","journal-title":"Digestion"},{"key":"10.1016\/j.mcna.2018.08.001_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000478-199006000-00001","article-title":"Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association","volume":"4","author":"Solcia","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.mcna.2018.08.001_bib38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1365-2036.2000.00768.x","article-title":"Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors","volume":"14","author":"Laine","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib39","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2007.03450.x","article-title":"Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas","volume":"26","author":"Singh","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4082\/kjfm.2012.33.5.272","article-title":"Use of proton pump inhibitor and risk of colorectal cancer: a meta-analysis of observational studies","volume":"33","author":"Ahn","year":"2012","journal-title":"Korean J Fam Med"},{"issue":"6","key":"10.1016\/j.mcna.2018.08.001_bib41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/00365521.2018.1450442","article-title":"Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences","volume":"53","author":"Waldum","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.mcna.2018.08.001_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1091-255X(00)80032-3","article-title":"Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids","volume":"4","author":"Theisen","year":"2000","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.mcna.2018.08.001_bib43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/carcin\/12.3.435","article-title":"Bacterial formation of N-nitroso compounds from administered precursors in the rat stomach after omeprazole-induced achlorhydria","volume":"12","author":"Calmels","year":"1991","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mcna.2018.08.001_bib44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2036.1995.tb00391.x","article-title":"Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy","volume":"9","author":"Kuipers","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","article-title":"Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study","volume":"67","author":"Cheung","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.mcna.2018.08.001_bib46","doi-asserted-by":"crossref","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.mcna.2018.08.001_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canep.2018.02.004","article-title":"Maintenance proton pump inhibition therapy and risk of oesophageal cancer","volume":"53","author":"Brusselaers","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.mcna.2018.08.001_bib48","doi-asserted-by":"crossref","first-page":"9083","DOI":"10.1158\/0008-5472.CAN-09-2518","article-title":"In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double strand breaks","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.mcna.2018.08.001_bib49","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/gutjnl-2013-305997","article-title":"Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis","volume":"63","author":"Singh","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.mcna.2018.08.001_bib50","doi-asserted-by":"crossref","first-page":"e0169691","DOI":"10.1371\/journal.pone.0169691","article-title":"Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a systematic review and meta-analysis","volume":"12","author":"Hu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.mcna.2018.08.001_bib51","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2036.2011.04874.x","article-title":"Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection","volume":"34","author":"Bavishi","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib52","doi-asserted-by":"crossref","first-page":"e0128004","DOI":"10.1371\/journal.pone.0128004","article-title":"Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis","volume":"10","author":"Lambert","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.mcna.2018.08.001_bib53","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ajg.2012.108","article-title":"Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis","volume":"107","author":"Kwok","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mcna.2018.08.001_bib54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jgh.12065","article-title":"Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis","volume":"28","author":"Deshpande","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.mcna.2018.08.001_bib55","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","article-title":"Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency","volume":"310","author":"Lam","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2018.08.001_bib56","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s10620-011-1589-y","article-title":"Association between proton pump inhibitor use and anemia: a retrospective cohort study","volume":"56","author":"Sarzynski","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.mcna.2018.08.001_bib57","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/BOR.0000000000000291","article-title":"Proton pump inhibitors and osteoporosis","volume":"28","author":"Andersen","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.mcna.2018.08.001_bib58","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/ajg.2011.113","article-title":"Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies","volume":"106","author":"Ngamruengphong","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mcna.2018.08.001_bib59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5527\/wjn.v5.i2.152","article-title":"Proton-pump inhibitor-induced hypomagnesemia: current research and proposed mechanisms","volume":"5","author":"William","year":"2016","journal-title":"World J Nephrol"},{"issue":"suppl 5","key":"10.1016\/j.mcna.2018.08.001_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2036.1999.00034.x","article-title":"Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy","volume":"13","author":"Lew","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00008571-199602000-00007","article-title":"Interaction of human liver cytochromes P450 in\u00a0vitro with LY307640, a gastric proton pump inhibitor","volume":"6","author":"VandenBranden","year":"1996","journal-title":"Pharmacogenetics"},{"issue":"suppl 3","key":"10.1016\/j.mcna.2018.08.001_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2036.1999.00021.x","article-title":"Review article: drug interactions with agents used to treat acid-related diseases","volume":"13","author":"Humphries","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2011-0431","article-title":"Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors","volume":"17","author":"Bezabeh","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.mcna.2018.08.001_bib64","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin","volume":"4","author":"Gilard","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.mcna.2018.08.001_bib65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2018.08.001_bib66","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2018.08.001_bib67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCOUTCOMES.114.001177","article-title":"Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review","volume":"8","author":"Melloni","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.mcna.2018.08.001_bib68","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mcna.2018.08.001_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.12926","article-title":"Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis","volume":"29","author":"Sun","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.mcna.2018.08.001_bib70","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","article-title":"Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine","volume":"128","author":"Ghebremariam","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2018.08.001_bib71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.ackd.2016.11.004","article-title":"Mechanisms of drug-induced interstitial nephritis","volume":"24","author":"Raghavan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.mcna.2018.08.001_bib72","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2147\/DDDT.S130568","article-title":"Proton pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies","volume":"11","author":"Yang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.mcna.2018.08.001_bib73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ndt\/gfw470","article-title":"The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis","volume":"33","author":"Nochaiwong","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.mcna.2018.08.001_bib74","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/ajg.2009.87","article-title":"Might the use of acid suppressive medications predispose to the development of eosinophilic esophagitis?","volume":"104","author":"Merwat","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mcna.2018.08.001_bib75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.dld.2013.08.128","article-title":"Use of proton pump inhibitors and subsequent risk of celiac disease","volume":"46","author":"Lebwohl","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.mcna.2018.08.001_bib76","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1060028016673859","article-title":"Association between proton pump inhibitors and microscopic colitis","volume":"51","author":"Law","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.mcna.2018.08.001_bib77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2710.2009.01100.x","article-title":"Proton pump inhibitors: predisposers to Alzheimer disease?","volume":"35","author":"Fallahzadeh","year":"2010","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.mcna.2018.08.001_bib78","doi-asserted-by":"crossref","first-page":"e015735","DOI":"10.1136\/bmjopen-2016-015735","article-title":"Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Xie","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.mcna.2018.08.001_bib79","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/AOG.0b013e31826af61a","article-title":"False alarms and pseudo-epidemics: the limitations of observational epidemiology","volume":"120","author":"Grimes","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.mcna.2018.08.001_bib80","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/gut.2005.086579","article-title":"Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK","volume":"55","author":"Garc\u00eda Rodr\u00edguez","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.mcna.2018.08.001_bib81","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","article-title":"Proton-pump inhibitor use and the risk for community-acquired pneumonia","volume":"149","author":"Sarkar","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2018.08.001_bib82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0141076814562718","article-title":"The environment and disease: association or causation? 1965","volume":"108","author":"Hill","year":"2015","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.mcna.2018.08.001_bib83","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:42:49Z","timestamp":1758418969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712518300920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0025712518300920"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2018.08.001","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton Pump Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}